QuickCool AB (publ): Investigates a proposal which will secure long term financing

Report this content

QuickCool AB (Publ) ("QuickCool") is investigating  a proposal for the financing of QuickCool until the CE-certification has been received.

The Board of QuickCool has been presented with a proposal to finance QuickCool’s running operations up to the granting of the required CE mark and certification of the QuickCool® SYSTEM. This long-term financing solution would allow QuickCool’s organization to focus on finalizing the development project and achieve the CE certification without spending time on financing issues, to free up resources on the core development with a view to shortening the project delay.

Göran Brorsson, Chairman of the Board: “Financing is a pressing issue for QuickCool AB, and has been so for some time. We are exploring this very interesting proposal which has the potential to provide a solution to QuickCool’s long term financial needs up to market launch of the QuickCool® SYSTEM. The proposed time frame is for the new financing to be in place before the end of October, although we are not in a position to disclose the details of the negotiations at this moment in time.”

For additional information, please contact: >
Fredrik Radencrantz, CEO
Phone: 046-286 38 40
E-mail: fredrik.radencrantz@quickcool.se

This information is such that QuickCool AB is required to make public in accordance with the EU’s market abuse regulation (MAR). The information was made publicly available by the Company’s contact person on 28 August 2019.

Quickcool is a Swedish medical technology company, whose business concept is to save lives and prevent brain damage in acute ischemia (Inadequate blood supply to the brain) by developing and providing a unique and globally patented cooling system, the Quickcool SYSTEM. Quickcool is active in the fast-growing market, Targeted Temperature Management (TTM), for brain-protective cooling treatment of patients with e.g. acute cardiac arrest and stroke. QuickCool’s solution protects the brain by cooling in the nasal cavity and thus takes advantage of the innate heat exchanger in the nose. QuickCool’s Intranasal method offers gentle and uninterrupted cooling treatment for sedated patients. Quickcool is listed on Spotlight Stock Market and conducts its business at Ideon Science Park in Lund. For more Information, please refer to www.quickcool.se 


Documents & Links